Gary Robb Biography and Net Worth



Gary Charles Robb serves as Chief Financial Officer, Secretary of the Company. From 2005 to 2011, Mr. Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc., a private fitness equipment and training company with operations in the United States, Europe and Asia. From 2003 to 2005, Mr. Robb was engaged in the private practice of law. From 2000 to 2002, he was Senior Vice President of Citadon, Inc. He also held positions in business development for Nomura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc. from 1996 to 1998. From 1992 to 1996, Mr. Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr. Robb earned a B.A. in English and Political Philosophy from Yale and a J.D. from Harvard Law School.

What is Gary Charles Robb's net worth?

The estimated net worth of Gary Charles Robb is at least $556,686.90 as of November 22nd, 2022. Mr. Robb owns 21,329 shares of Corcept Therapeutics stock worth more than $556,687 as of November 25th. This net worth evaluation does not reflect any other assets that Mr. Robb may own. Additionally, Mr. Robb receives an annual salary of $900,080.00 as CFO at Corcept Therapeutics. Learn More about Gary Charles Robb's net worth.

How old is Gary Charles Robb?

Mr. Robb is currently 59 years old. There are 6 older executives and no younger executives at Corcept Therapeutics. The oldest executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, Pres, CEO & Director, who is 65 years old. Learn More on Gary Charles Robb's age.

What is Gary Charles Robb's salary?

As the CFO of Corcept Therapeutics Incorporated, Mr. Robb earns $900,080.00 per year. The highest earning executive at Corcept Therapeutics is Dr. Joseph K. Belanoff M.D., Co-Founder, Pres, CEO & Director, who commands a salary of $1,690,000.00 per year. Learn More on Gary Charles Robb's salary.

How do I contact Gary Charles Robb?

The corporate mailing address for Mr. Robb and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected] Learn More on Gary Charles Robb's contact information.

Has Gary Charles Robb been buying or selling shares of Corcept Therapeutics?

During the last quarter, Gary Charles Robb has sold $385,908.42 in Corcept Therapeutics stock. Most recently, Gary Charles Robb sold 4,814 shares of the business's stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $26.03, for a transaction totalling $125,308.42. Following the completion of the sale, the insider now directly owns 21,329 shares of the company's stock, valued at $555,193.87. Learn More on Gary Charles Robb's trading history.

Who are Corcept Therapeutics' active insiders?

Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Lyon (CAO), Sean Maduck (Insider), Gary Robb (CFO), and Daniel Swisher, Jr. (Director). Learn More on Corcept Therapeutics' active insiders.

Are insiders buying or selling shares of Corcept Therapeutics?

In the last year, insiders at the biotechnology company sold shares 12 times. They sold a total of 507,306 shares worth more than $13,049,597.88. The most recent insider tranaction occured on November, 22nd when insider Gary Charles Robb sold 4,814 shares worth more than $125,308.42. Insiders at Corcept Therapeutics own 18.6 % of the company. Learn More about insider trades at Corcept Therapeutics.

Information on this page was last updated on 11/22/2022.

Gary Charles Robb Insider Trading History at Corcept Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2022Sell4,814$26.03$125,308.4221,329View SEC Filing Icon  
11/17/2022Sell10,000$26.06$260,600.0039,544View SEC Filing Icon  
9/7/2022Sell50,000$26.06$1,303,000.0049,544View SEC Filing Icon  
7/6/2022Sell45,000$26.00$1,170,000.0024,123View SEC Filing Icon  
5/19/2022Sell6,127$19.57$119,905.3936,446View SEC Filing Icon  
5/17/2022Sell28,745$19.55$561,964.7542,701View SEC Filing Icon  
3/17/2022Sell7,512$24.68$185,396.16View SEC Filing Icon  
9/15/2021Sell47,853$20.49$980,507.97View SEC Filing Icon  
9/13/2021Sell6,341$20.89$132,463.49136,507View SEC Filing Icon  
4/23/2021Sell10,000$24.02$240,200.0075,638View SEC Filing Icon  
2/12/2021Sell112,100$28.22$3,163,462.00197,738View SEC Filing Icon  
12/12/2018Sell25,000$19.01$475,250.0021,858View SEC Filing Icon  
5/4/2017Buy5,600$9.75$54,600.006,858View SEC Filing Icon  
See Full Table

Gary Charles Robb Buying and Selling Activity at Corcept Therapeutics

This chart shows Gary Charles Robb's buying and selling at Corcept Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Corcept Therapeutics Company Overview

Corcept Therapeutics logo
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $26.10
Low: $26.01
High: $26.29

50 Day Range

MA: $26.65
Low: $24.51
High: $29.96

2 Week Range

Now: $26.10
Low: $15.82
High: $30.14

Volume

86,883 shs

Average Volume

622,008 shs

Market Capitalization

$2.81 billion

P/E Ratio

26.10

Dividend Yield

N/A

Beta

0.56